This paper deals with the study of an HIV dynamics model with two target cells, macrophages and CD4 + T cells and three categories of infected cells, short-lived, long-lived and latent in order to get better insights into HIV infection within the body. The model incorporates therapeutic modalities such as reverse transcriptase inhibitors (RTIs) and protease inhibitors (PIs). The model is incorporated with distributed time delays to characterize the time between an HIV contact of an uninfected target cell and the creation of mature HIV. The effect of antibody on HIV infection is analyzed. The production and removal rates of the ten compartments of the model are given by general nonlinear functions which satisfy reasonable conditions. Nonnegativity and ultimately boundedness of the solutions are proven. Using the Lyapunov method, the global stability of the equilibria of the model is proven. Numerical simulations of the system are provided to confirm the theoretical results. We have shown that the antibodies can play a significant role in controlling the HIV infection, but it cannot clear the HIV particles from the plasma. Moreover, we have demonstrated that the intracellular time delay plays a similar role as the Highly Active Antiretroviral Therapies (HAAT) drugs in eliminating the HIV particles.
Introduction
Modeling the HIV dynamics has received considerable attention from mathematicians during the recent decades . The first HIV dynamics model is proposed by Nowak and Bangham [1] as:
where s, y and p are the concentrations of the CD4 + T cells, infected cells and HIV particles; ρ, δ and λ represent the production, death and infection rates of the uninfected CD4 + T cells, respectively; η and g are the death rate constants of the infected cells and free HIV, respectively; N is the average number of HIV particles generated in the lifetime of the infected cells. A class of latently infected cells has been modeled in the HIV dynamics in [23] [24] [25] [26] . Elaiw et al. [27] have extended model (1)-(3) by considering distributed time delays, B cells (x), and three categories of infected cells, short-lived (y), long-lived (u) and latent (w) as: s = π(s (t)) − λΥ(s (t) , p (t)), (4) 3 (u (t)), (7) p = Nηψ 2 (y (t)) + Mνψ 3 (u (t)) − gψ 4 (p (t)) − µψ 4 (p (t))ψ 5 (x (t)), (8) x = rψ 4 (p (t))ψ 5 (x (t)) − ωψ 5 (x (t)), (9) where f i (τ) e −µ i τ over the time interval [0, h i ] , i = 1, 2, 3 represents the probabilities that uninfected cells contacted by HIV at time t − τ survived τ time units and become infected at time t; Υ, π, ψ j , j = 1, ..., 5 are general nonlinear functions. The probability distribution function f i (τ) satisfies f i (τ) > 0 and
where υ > 0. Let us denote Θ i (τ) = f i (τ)e −µ i τ and F i =
Model (4)- (9) assumes that the HIV infects one category of target cells, CD4 + T cells. However, Perleson et al. have observed that after the rapid first phase of decay during the initial 1-2 weeks of an antiretroviral treatment, plasma virus levels declined at a considerably slower rate [28] . This second phase of viral decay was attributed to the turnover of infected macrophages. Therefore, the HIV model with two categories of target cells, CD4 + T cells and macrophages is more accurate than that model with only one category target cells, CD4 + T cells. As a result, more accurate drug efficacy can be determined when using the HIV model with two classes of target cells. Recently, many efforts have been devoted to the analysis of various mathematical models of HIV dynamics with two categories of target cells (see, e.g., [29] [30] [31] [32] [33] [34] [35] [36] [37] ). However, in these papers, the production and removal rates of the HIV particles and cells are given by linear functions; moreover, only one or two classes of infected cells are considered.
The aim of the present paper is to propose and analyze an HIV dynamics model which extends model (4)- (9) and describes the dynamics of HIV with two categories of target cells, CD4 + T cells and macrophages. We study the basic and global properties of the model. Using Lyapunov function and LaSalle's invariance principle, we have established the global asymptotic stability of the three equilibria of the model. We have shown that the antibodies can reduce the HIV level, but they cannot clear the HIV particles completely. The effect of HAART drugs and intracellular time delays in stabilizing the HIV dynamics system around the infection-free equilibrium are shown. The importance of considering the second class of target cells (macrophages) in the HIV dynamics is also shown.
The rest of the paper is organized as follows: in Section 2, we present the HIV model and study its basic properties. In Section 3, the global stability of three equilibria is established. In Section 4, we offer some numerical simulations to confirm our analytical results. The paper ends with some conclusions and discussion in Section 5.
Mathematical Model
We propose the following model:
where i = 1 for the CD4 + T cells and i = 2 for the macrophages. We have Θ ji (τ)dτ; thus 0 < F ji ≤ 1, j = 1, ..., 5, i = 1, 2. We assume that:
Hypothesis 2 (H2). (i)
Υ i (s i , p) > 0 and Υ i (0, p) = Υ i (s i , 0) = 0 for s i , p > 0, (ii) ∂Υ i (x i ,p) ∂s i > 0, ∂Υ i (s i ,p) ∂p > 0 and, ∂Υ i (s i ,0) ∂p > 0 for all s i , p > 0, (iii) d ds i ∂Υ i (s i , 0) ∂p > 0 for s i > 0.
Hypothesis 3 (H3).
(i) ψ ji (η) > 0 for η > 0, ψ ji (0) = 0, j = 1, ..., 4, i = 1, 2, (ii) ψ ji (η) > 0, ψ 42 (η) > 0 for η > 0, j = 1, 2, 3, i = 1, 2, ψ 41 (η) > 0, for η ≥ 0; (iii) there are α ji > 0, j = 1, ..., 4, i = 1, 2, such that ψ ji (η) ≥ α ji η for η ≥ 0.
Hypothesis 4 (H4).
Remark 1. From H1-H4, we have
We consider systems (10)- (15) with the initial conditions:
where ς = max {h 11 , h 12 , h 21 , h 22 , h 31 , h 32 , h 41 , h 42 , h 51 , h 52 } and denoted by C is the Banach space of continuous functions mapping the interval [−ς, 0] into R ≥0 and (ϕ 1 (θ) , ..., ϕ 10 (θ)) ∈ C [−ς, 0] , R 10 ≥0 . According to [38] , there exists a unique solution for system (10)- (15) with initial (16).
Properties of Solutions
Lemma 1. Suppose that H1-H3 hold, then the solutions of system (10)-(15) are non-negative and ultimately bounded.
The proof Lemma 1 is given in Appendix A. Lemma 1 shows that
is positively invariant with respect to system (10)-(15).
Equilibria
The basic reproduction number R 0 of system (10)-(15) is given by:
The equilibria of system (10)-(15) satisfy the following equations:
From Equation (22), we have x = 0 or p = ψ −1 41 (ω/r). Let us define
where
. It follows from Equations (17)-(21) that: (17), (23) , and (24), we obtain
Equation (25) has two possible solutions, Λ 4 = 0 and Λ 4 = 0. The solution Λ 4 = 0 implies s i = s 0 i which gives the infection-free equilibrium Π 0 (s 0 1 , s 0 2 , 0, 0, 0, 0, 0, 0, 0, 0). The other solution Λ 4 = 0 admits an antibody-inactivated infection equilibrium Π 1 (s 1 ,s 2 ,w 1 ,w 2 ,ỹ 1 ,ỹ 2 ,ũ 1 ,ũ 2 ,p, 0), where
Now, we consider the other solution of Equation (22) 
It follows from Equations (21) and (24) that
Thus,x > 0 when
ψ 41 (p) > 1. Define R 1 as follows:
which represents the antibody immune response activation number.
If R 1 > 1, thenx = ψ −1 42 g µ (R 1 − 1) > 0, and there exists an antibody-activated infection equilibrium Π 2 (s 1 ,s 2 ,w 1 ,w 2 ,ȳ 1 ,ȳ 2 ,ū 1 ,ū 2 ,p,x). Clearly, from H2 and H4, we have Theorem 2. Suppose that hypotheses H1-H4 are satisfied, Π 1 exists and R 1 ≤ 1, then Π 1 is globally asymptotically stable. Theorem 3. Let hypotheses H1-H4 hold true and R 1 > 1, then Π 2 is globally asymptotically stable.
Global Stability
The proofs of Lemma 2 and Theorems 1-3 are given in Appendix A.
Numerical Simulations
We choose
We have
Then, H1 is satisfied.
Then,
It follows that, H2 is satisfied. One can show that function ψ ji satisfies H3. Moreover,
Therefore, H4 holds true. In addition, we take a particular form of the probability distributed function as:
where δ (.) is the Dirac delta function and τ ji ∈ 0, h ji , j = 1, ..., 5, i = 1, 2 are constants. When h ji → ∞, we have:
Hence, model (10)-(15) becomes:
The parameters R 0 and R 1 for this application are given by:
In Table 1 , we present the values of parameters of system (27)- (36) . We let τ ij = τ, µ ij = µ e , i = 1, 2, ..., 5, j = 1, 2. We solve the system of delay differential Equations (27)-(36) with constant delays by using dde23 program in MATLAB (version 7). 
Stability of the Equilibria of the System
In this part of simulation, we choose three different initial conditions:
We study three cases by choosing ε 1 , ε 2 , τ and r. In Figures 1-10 , we want to confirm our global stability results given in Theorems 1-3, by showing that any initial points taken from a feasible set the trajectory of the system will tend to one of the three equilibria of the system.
Case (I):
Choose ε 1 = 0.7, ε 2 = 0.7, τ = 0.85 and r = 0.009, which gives R 0 = 0.2778 < 1 and R 1 = 0.1156 < 1. Figures 1-10 show that the concentrations of the uninfected CD4 + T cells and macrophages are increasing and reach the values s 0 1 = 1003.3 and s 0 2 = 16, respectively. In other words, concentrations of short-lived, long-lived and latently infected cells as well as HIV particles and B cells converge to zero. This confirms the result of Theorem 1, which is Π 0 is globally asymptotically stable. As a result, the HIV is removed from the plasma.
Case (II):
We take ε 1 = 0.2, ε 2 = 0.3, τ = 0.5 and r = 0.004. For these values, Figures 1-10 , we can see that for IC1-IC3 the state Π 1 = (346.147, 7.549, 6.054, 0.31, 7.265, 0.217, 44.397, 0.341, 12.688, 0.0) is reached, where the HIV infection is chronic and the antibody immune system is inactive. Hence, Theorem 2 is confirmed.
Case (III): ε 1 = 0.2, ε 2 = 0.3, τ = 0.5 and r = 0.05. Then, we calculate R 0 = 3.1775 > 1 and R 1 = 2.4497 > 1. From Figures 1-10, we see that for IC1-IC3, the state Π 2 = (773.46, 13.594, 2.132, 0.088, 2.559, 0.062, 15.638, 0.097, 2, 7.405) is reached, where the HIV infection is chronic and the antibody immune system is active. Thus, Theorem 3 is confirmed.
We mention that, R 0 does not depends on the parameters ω, r and µ. This fact seems to suggest that antibody immune response does not play a role in clearing the HIV particles. From above, we can see that R 1 can be increased by increasing the value of r. When we compare the Cases (II) and (III), we can see from the figures that, when the antibody immune response is activated (i.e., R 1 > 1), it reduces the concentrations of HIV free particles and infected (short-lived, long-lived and latent) cells and increases the concentration of uninfected target cells. It means that the antibody immune response can play a significant role in controlling the infection.
Effect of the Drug Efficacy on the Stability of the System
We take ε 1 = ε 2 = ε, τ = 0.5, and r = 0.05. In Table 2 , we present the values of R 0 and R 1 for selected values of ε. It is seen that the values of R 0 and R 1 are decreased as ε is increased. Using the values of the parameters given in Table 1 , we obtain the following cases:
(i) if 0 ≤ ε < 0.54636, then R 1 > 1, Π 2 exists and it is globally asymptotically stable, (ii) if 0.54636 ≤ ε < 0.58032, then R 1 ≤ 1, Π 1 exists and it is globally asymptotically stable and (iii) if 0.58032 ≤ ε ≤ 1, then R 0 ≤ 1 and Π 0 is globally asymptotically stable.
Thus, the results of Theorems 1-3 and the numerical results are compatible. Therefore, we can say that treatment with sufficient drug efficacy can successfully clear the virus from the plasma. 16 , 0, 0, 0, 0, 0, 0, 0, 0) 1 0.8654 0.7 Π 0 = (1003.3, 16, 0, 0, 0, 0, 0, 0, 0, 0) 0.5114 0.4602
Effect of the Time Delay on the Stability of the System
Choose ε 1 = ε 2 = 0, and r = 0.05. The initial conditions are considered to be (s 1 , [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] and Table 3 show the effect of the time delay parameter τ on the stability of Π 0 , Π 1 and Π 2 . It can be seen that, as τ is increased, the concentration of the uninfected target cells is increased, while the concentrations of short-lived, long-lived and latently infected cells, free HIV particles and B cells are decreased. From Figures 11-20, we can see that, in the case of smaller values of τ, the trajectory of system will converge to Π 2 . When the value of τ is increased, the trajectory will converge to Π 1 and finally approach Π 0 . From a biological point of view, the intracellular time delay plays a similar role as the anti-HIV drugs in eliminating the virus. We observe that sufficiently large delay suppresses viral replication and clears the virus from the body. This gives us some suggestions on new drugs to prolong the increase in the intracellular delay period. 
Discussion
All of the HIV infection mathematical models with three categories of infected cells, short-lived, long-lived and latent presented in the literature have studied the HIV infection and production in one class of target cells, CD4 + T cells. However, it has been reported in several papers that HIV can infect both CD4 + T cells and macrophages. In this paper, we have proposed an HIV infection model with three categories of infected cells and two classes of target cells, CD4 + T cells and macrophages. We have incorporated multiple distributed time delays to characterize the time between an HIV contacts an uninfected target cell and the creation of mature HIV particles. The effect of antibody immune response has been modeled. The production and removal rates of all compartments are represented by general nonlinear functions. The incidence rate of infection is also given by a general nonlinear function. The model can be seen as a generalization of several HIV dynamics models presented in the literature. We have shown that the solutions of the model are nonnegative and ultimately bounded, which ensures the well-posedness of the model. We have derived two threshold numbers R 0 (the basic reproduction number) and antibody immune response activation number R 1 , which determine the stability of the three equilibria of the model. We have investigated the global stability of the equilibria of the model by using Lyapunov method and LaSalle's invariance principle. We have proven that (i) if R 0 ≤ 1, then the infection-free equilibrium Π 0 is globally asymptotically stable and the HIV is predicted to be completely cleared from the HIV infected patients, (ii) if the antibody-inactivated infection equilibrium Π 1 exists then it is globally asymptotically stable and a chronic HIV infection with inactive antibody immunity is attained, and (iii) if R 1 > 1, then the antibody-activated infection equilibrium Π 2 is globally asymptotically stable and a chronic HIV infection with active antibody immunity is attained. We have conducted numerical simulations and have shown that both the theoretical and numerical results are consistent.
Our analysis extends the results presented in [27] , where the global stability was analyzed for a model with one target cell population. When we consider the HIV dynamics with only one class of target cells, CD4 + T cells, then model (10)- (15) leads to the following model:
Let us define the overall HAART effect as ε e = ε 1 + ε 2 − ε 1 ε 2 [39] . If ε e = 0, then the HAART has no effect, if ε e = 1, the HIV-1 growth is completely halted. Consequently, the basic reproduction number for system (37)-(42) is given by
For comparison purposes, we assume that h = f = 1; then, the basic reproduction number for system (27)-(36) can be written as:
where R M 0 (ε e ) is the basic reproduction number of a model that describes the HIV dynamics with only macrophages and neglecting the CD4 + T cells. For system (37)-(42), one can determine drug efficacy ε C e such that R C 0 (ε C e ) = 1 as:
Therefore, if ε C e ≤ ε e ≤ 1, then R C 0 (ε C e ) ≤ 1. For system (27)- (36) , one can also determine the drug efficacy ε CM e such that R CM 0 (ε CM e ) = 1 as:
Therefore, if ε CM e ≤ ε e ≤ 1, then R CM 0 (ε CM e ) ≤ 1. Assume that R C 0 (0) > 1, then Π 0 of system (37)-(42) is unstable in the absence of treatment. Since R C 0 (0) < R CM 0 (0), then ε C e < ε CM e . Therefore, if we apply drugs with ε e such that ε C e ≤ ε e < ε CM e , this guarantees that R C 0 (ε e ) ≤ 1 and the system (37)-(42) can be stabilized around Π 0 ; however, R CM 0 (ε e ) > 1 and then Π 0 of (27)-(36) is unstable. Therefore, more accurate drug efficacy ε e is determined when using the model with two classes of target cells. This shows the importance of considering the effect of the macrophages in the HIV dynamics. 
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Appendix A
The following equalities will be used in the proofs of the Theorems 2 and 3:
Proof of Lemma 1. Denote k = (s 1 , s 2 , w 1 , w 2 , y 1 , y 2 , u 1 , u 2 , p, x) T , L = (L 1 , L 2 , ..., L 10 ) T . Then, systems (10)-(15) can be written ask (t) = L (k (t)), where
We have L j (k (t)) k(t)∈R 10 >0 ≥ 0, j = 1, ..., 10.
Applying Lemma 2 in [40] , we get k(t) ∈ R 10 ≥0 for all t ≥ 0. Equation (10) 
Moreover, we let G 3 (t) = p(t) + µ r x(t). Then,
where σ 3 = min{gα 41 , ωα 42 }. Hence,
, and x (t) are ultimately bounded.
Proof of Theorem 1. Define a Lyapunov functional U 0 (s 1 , s 2 , w 1 , w 2 , y 1 , y 2 , u 1 , u 2 , p, x) as follows:
where k 1i , ..., k 5i , k 61 and k 62 satisfy the following equations:
The solution of Equations (A2) is given by
It is seen that U 0 (s 1 , s 2 , w 1 , w 2 , y 1 , y 2 , u 1 , u 2 , p, x) > 0 for all s 1 , s 2 , w 1 , w 2 , y 1 , y 2 , u 1 , u 2 , p, x > 0 and U 0 s 0 1 , s 0 2 , 0, 0, 0, 0, 0, 0, 0, 0 = 0. We calculate dU 0 dt along the trajectories of systems (10)-(15) as follows:
Simplifying Equation (A3) and utilizing π(s 0 i ) = 0, we obtain
− k 62 ωψ 42 (x).
By H1 and H2, we get
Therefore, if R 0 ≤ 1, then dU 0 dt ≤ 0 for s i , p, x ∈ (0, ∞). Clearly, dU 0 dt = 0 at Π 0 . Applying LaSalle's invariance principle, we get that Π 0 is globally asymptotically stable.
Proof of Lemma 2. From H1 and H2, we get
fors i ,s i ,p,p > 0. From H4, we get
We first prove that sgn(p −p) = sgn(s i −s i ). Assume that sgn(p −p) = sgn(s i −s i ). Using the equilibrium conditions of Π 1 and Π 2 , we get
Therefore, from the inequalities (A4)-(A6), we obtain sgn (s i −s i ) = sgn (s i −s i ), and this is a contradiction. It follows that sgn (p −p) = sgn (s i −s i ) . Using Equation (26) and the definition of R 1 , we get
Thus, from inequalities (A5) and (A7), we obtain sgn(R 1 − 1) = sgn(p −p).
Proof of Theorem 2. Let U 1 (s 1 , s 2 , w 1 , w 2 , y 1 , y 2 , u 1 , u 2 , p, x)
It can be seen that U 1 (s 1 , s 2 , w 1 , w 2 , y 1 , y 2 , u 1 , u 2 , p, x) > 0 for all s 1 , s 2 , w 1 , w 2 , y 1 , y 2 , u 1 , u 2 , p, x > 0 and U 1 (s 1 ,s 2 ,w 1 ,w 2 ,ỹ 1 ,ỹ 2 ,ũ 1 ,ũ 2 ,p, 0) = 0. Evaluating dU 1 dt along the solutions of systems (10)-(15), we obtain:
Collecting terms of Equation (A8) and applying π i (s i ) = λ i Υ i (s i ,p), we get
Using the equilibrium conditions for Π 1 :
we have
Using the Equalities (A1) withŝ i =s i ,ŵ i =w i ,ŷ i =ỹ i ,û i =ũ i andp =p, we have
Equation (A9) becomes
From H1, H2 and H4, we have 
Note that, U 2 (s 1 , s 2 , w 1 , w 2 , y 1 , y 2 , u 1 , u 2 , p, x) > 0 for all s 1 , s 2 , w 1 , w 2 , y 1 , y 2 , p, x > 0 and U 2 (s 1 ,s 2 ,w 1 ,w 2 ,ȳ 1 ,ȳ 2 ,ū 1 ,ū 2 ,p,x) = 0. Calculating dU 2 dt along the solutions of system (10)-(15), we get 
Collecting terms of Equation (A10), applying π i (s i ) = λ i Υ i (s i ,p) and using the equilibrium conditions for Π 2 :
